Mutated EGFR-IN-1 is primarily used in cancer research, particularly in studies focused on non-small cell lung cancer (NSCLC). It acts as an inhibitor targeting mutated epidermal growth factor receptor (EGFR), which is often implicated in the development and progression of certain cancers. By blocking the activity of these mutated receptors, it helps to slow down or halt the growth of cancer cells. This makes it a valuable tool in preclinical studies aimed at understanding resistance mechanisms to EGFR-targeted therapies and in the development of new treatment strategies. Additionally, it is utilized in screening assays to identify potential therapeutic compounds that can overcome resistance in EGFR-mutated cancers.